RxDoctor Payments Data

Josiah Child, MD

Internal Medicine · Santa Fe, NMNPI 1194807800

Payments from drug & device makers

$1,038in general payments, 2019–2025

Across 33 payments — averaging $31.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$405
  • AbbVie$162
  • Boehringer Ingelheim$151
  • Novo Nordisk$76
  • Verona Pharma, Inc.$49
  • Irhythm Technologies, Inc.$34
  • plus $160 from 7 others

What the payments were for

  • Food & beverage$1,038100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,038 in reported general payments places this provider in the 85th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$145,385
Medicare patients
239
Services billed
2,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$41,761
EliquisApixaban49$39,793
JardianceEmpagliflozin57$39,060
MounjaroTirzepatide16$23,924
CreonLipase/Protease/Amylase11$16,387
LinzessLinaclotide30$15,575
BelbucaBuprenorphine Hcl13$11,445
Repatha SureclickEvolocumab15$10,092
MyrbetriqMirabegron19$9,771
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,720
PaxlovidNirmatrelvir/Ritonavir30$4,288
Rosuvastatin Calcium123$2,248
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,061
Levothyroxine Sodium109$1,456
Celecoxib72$1,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$76$41,76131 claims
Boehringer IngelheimJardiance$151$39,06057 claims
AbbVieCreon, Linzess, Synthroid$162$33,07861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →